CBPartners’ Value, Access, and Pricing teams are composed of the industry’s leading thought leaders and seasoned engagement managers who work relentlessly to support client value, access, and pricing.
Showing 5 of 30 posts
September 8, 2021 | Blogs
In part one of this two-part series about non-traditional players in the healthcare sector, CBPartners explores the increasingly attractive market despite the risk of an expensive failed venture by analyzing the success and failures of four non-traditional players.
September 1, 2021 | Blogs
CBPartners reviews the COVID-driven changes to patients, providers, payers, clinical research, and pharmaceutical distribution within the US.
August 26, 2021 | Blogs
What Market Access Opportunities Exist for Oncology Products in China? An Analysis of Oncology Product Inclusion in the 2020 NRDL
Fourteen oncology drugs were successfully negotiated and included in the 2020 NRDL. As the new prices became effective from March 01, 2021, several key features and trends have been observed.
August 24, 2021 | Blogs, Infographics
A recent study of the review of new medicines by regulatory and HTA bodies has revealed areas of misalignment in their processes, highlighting unique challenges in the pathway to patient access.
August 19, 2021 | Blogs
What Market Access Opportunities Exist for Rare Disease Products in China? An Analysis of Rare Disease Product Inclusion in the 2020 NRDL
The first of two articles investigating market access opportunities in China - CBPartners’ Asia-Pacific Center of Excellence analyzes the opportunities that lie ahead for rare disease products based on 2020 NRDL update inclusion.